Upload
Featured Recent Articles Topics Login Upload

Search Results for 'trials endpoints'

trials endpoints published presentations and documents on DocSlides.

Positive Impacts of Developing Novel Endpoints
Positive Impacts of Developing Novel Endpoints
by ryotheasy
Generated by Mobile Technology for . Use in Clinic...
End-points utilized in breast cancer
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
End-points utilized in
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
Designing Phase I Trials With Targeted Agents:
Designing Phase I Trials With Targeted Agents:
by giovanna-bartolotta
Challenging Tradition. Chia-Chi (Josh) Lin, MD, P...
Pragmatic Clinical Trials: Challenges with Clinical Event Ascertainment using
Pragmatic Clinical Trials: Challenges with Clinical Event Ascertainment using
by anastasia
RWD. Frank W. Rockhold, PhD. Professor of Biostati...
Regulatory aspects and review
Regulatory aspects and review
by mary
of EMA authorized . biosimilars. Session “Biosim...
An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-
An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-
by elyana
. Natalie Dimier and Sue Todd. University of Readi...
Session I: DHT-Derived Novel Endpoint Development: Current Landscape
Session I: DHT-Derived Novel Endpoint Development: Current Landscape
by deborah
Elektra Papadopoulos, . FDA/CDER. Lindsay Kehoe, ....
Analysis of Multiple End Points in Clinical trials
Analysis of Multiple End Points in Clinical trials
by roberts
. By . Trusha Patel and Sirisha . Davuluri. “An ...
Are All Novel Insulins Proven to Be Equally Safe?
Are All Novel Insulins Proven to Be Equally Safe?
by phoebe-click
Agenda. Introduction/Background. CV Safety With I...
Introduction, Meeting Objectives and roadmap
Introduction, Meeting Objectives and roadmap
by jaxson
Roy Freeman, MD. Professor of Neurology, Harvard M...
Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD
Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD
by victoria
Raye Z. Litten, Ph.D.. Daniel Falk, Ph.D. (Discuss...
Critical Issues in the Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD
Critical Issues in the Exploration of Endpoints for Pivotal Clinical Trials to Treat AUD
by byrne
Daniel Falk, Ph.D. (Discussant). Division of Treat...
Center for Drug Evaluation and Research CDER ClinicalMedical
Center for Drug Evaluation and Research CDER ClinicalMedical
by pagi
Additional copies are available from: Office of Co...
Biomarkers A   biological marker is
Biomarkers A   biological marker is
by madison
a measurable indicator . that . can . tell . us so...
White Paper S
White Paper S
by harmony
trengthening the Accelerated Approval Pathway1STRE...
Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?
Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?
by tawny-fly
Recruitment of Female Sex Workers in HIV Preventi...
“Stronger Together We are”
“Stronger Together We are”
by faustina-dinatale
Daniel J. Sargent, PhD. 1970-2016. Wore Many hats...
Exploration of Endpoints for Pivotal Clinical Trials to Tre
Exploration of Endpoints for Pivotal Clinical Trials to Tre
by yoshiko-marsland
Raye Z. Litten, Ph.D.. Daniel Falk, Ph.D. (Discus...